YouTubeFacebookLinkedInTwitterinstagramrss

BioIVT Announces the Launch of its Next-generation Sequencing Service



By Bio-IT World News Staff

December 16, 2019 | BioIVT today launched its Next-generation Sequencing (NGS) Service, which combines the company’s expertise in human tissue procurement, specimen selection, sample preparation and project management with its in-house NGS capabilities. BioIVT now offers both standard and custom NGS services, including sample extraction, library preparation, sequencing and bioinformatics.

BioIVT experts are involved in all aspects of the project, starting with determining the mutations of interest and their incidence in the general population and in BioIVT-specific results (if known). The team can also assist with independent validation or verification of an existing assay or with exploratory work.

Once the target cohort has been identified, BioIVT can supply the required samples either from existing inventory or via a custom procurement process.

The BioIVT team has more than seven years of hands-on library preparation and sample analysis experience and can employ NGS, quantitative reverse transcription polymerase chain reaction (qRT-PCR), Sanger/pyrosequencing, and immunohistochemistry-based solutions to analyze the mutations.

“Our new NGS Service brings together expertise from across BioIVT, including biospecimen procurement, project design, project management, library prep, sequencing and data analysis,” BioIVT Chief Executive Officer Jeffrey Gatz said in a press release. “This service also builds upon our acquisition of Asterand Biosciences with our clients having immediate access to hundreds of thousands of banked specimens. We are also constantly increasing our bank through our clinical network with samples procured following industry best practices and meeting our ASTERAND human tissue standards.”

Depending on the project requirements, BioIVT can either provide the final data analysis or the required tissue in a fit-for-purpose format, such as slides, curls or blocks, ready for further study by the client’s research team.

For cancer research, BioIVT has both formalin-fixed, paraffin-embedded (FFPE) and frozen tumor specimens with known mutation statuses (both mutation positive and wild-type) available and ready to ship. Associated serum and plasma may also be available for these specimens.

BioIVT continues to evolve its mix of services and technologies so that it can be the best research partner possible for its clients as they develop new drugs and diagnostics to advance healthcare.

View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1